Zhejiang East Asia Pharmaceutical (SHA:605177) subsidiary Zhejiang Dongbang Pharmaceutical acquired the European CEP certificate for Cefaclor API (enzymatic method), according to a Monday filing with the Shanghai bourse.
Cefaclor is an antibacterial drug used to treat a variety of infections.
The acquisition of the certificate meant that the company's cefaclor API (enzyme method) had obtained access to the European market, which will help expand sales.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。